Metabolism, including glycolysis, oxidative phosphorylation, fatty acid oxidation, and other
metabolic pathways, impacts the phenotypes and functions of immune cells. The metabolic …

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …

The mammalian gut contains a large, complex community of microorganisms collectively
termed the microbiota. It is increasingly appreciated that gut microbes are closely integrated …

The E4 allele of Apolipoprotein E (APOE) is associated with both metabolic dysfunction and
a heightened pro-inflammatory response: two findings that may be intrinsically linked …

Alzheimer's disease (AD) is currently defined by the aggregation of amyloid-β (Aβ) and tau
proteins in the brain. Although biofluid biomarkers are available to measure Aβ and tau …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive
decline, the neuropathological formation of amyloid-beta (Aβ) plaques and neurofibrillary …

Alzheimer's disease (AD) is a degenerative brain disorder and the most common form of
dementia. AD pathology is characterized by senile plaques and neurofibrillary tangles …

Brain metabolism is comprised in Alzheimer's disease (AD) and Parkinson's disease (PD).
Since the brain primarily relies on metabolism of glucose, ketone bodies, and amino acids …

The ability of endocannabinoid (eCB) to change functional microglial phenotype can be
explored as a possible target for therapeutic intervention. Since the inhibition of fatty acid …

One of the most striking hallmarks shared by various neurodegenerative diseases, including
Alzheimer's disease (AD), is microglia-mediated neuroinflammation. The main pathological …